<DOC>
	<DOCNO>NCT03006315</DOCNO>
	<brief_summary>Enrolled participant health status track use mobile health-monitoring device undergo chemotherapy multiple myeloma .</brief_summary>
	<brief_title>Mobile Health Device Study Myeloma Patients</brief_title>
	<detailed_description>Newly diagnose multiple myeloma participant receive induction chemotherapy continuously bio-monitored baseline ( 1-7 day prior treatment initiation ) induction chemotherapy completion 6 cycle use Garmin Vivofit wearable device . For patient continue ASCT , patient bio-monitored 90 day post ASCT . The study include total 40 newly diagnose multiple myeloma participant two cohort 20 patient cohort ( Cohort A B ) . Cohort A comprised patient &lt; 65 year . Cohort B comprise patient &gt; /= 65 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Inclusion Criteria Newly diagnose Multiple Myeloma participant clinical histological confirmation diagnosis plan receive chemotherapy eligible : Clonal plasma cell ≥ 10 % Measureable disease within past 4 week define one following : Serum monoclonal protein ≥ 1.0 g/dL Urine monoclonal protein &gt; 200 mg/24 hour Involved serum immunoglobulin free light chain &gt; 10 mg/dL AND abnormal kappa/lambda ratio Newly diagnose Multiple Myeloma patient evidence underlying end organ damage and/or myeloma define event attribute underlying plasma cell proliferative disorder meeting least one following : Hypercalcemia : serum calcium &gt; 0.25 mmol/L ( &gt; 1 mg/dL ) upper limit normal ≥ 2.75 mmol/L ( 11 mg/dL ) Anemia : hemoglobin value &lt; 10 g/dL &gt; 2 g/dL low limit normal Bone disease : ≥ 1 lytic lesion skeletal Xray , CT , PETCT . For patient 1 lytic lesion , bone marrow demonstrate ≥ 10 % clonal plasma cell Clonal bone marrow plasma cell percentage ≥ 60 % Involved/uninvolved serum free light chain ratio ≥100 involve free light chain &gt; 100 mg/L &gt; 1 focal lesion magnetic resonance imaging study ( lesion must &gt; 5 mm ) size All study participant require receive primary chemotherapy treatment Memorial Sloan Kettering facility , include regional outpatient site . All study participant require smart phone tablet device compatible Garmin Vivofit device . Exclusion Criteria Plasma cell leukemia POEMS syndrome Amyloidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>garmin vivofit</keyword>
</DOC>